Dentists in Victor, ID Accepting Medicare
3 Dentists found. Showing 1 - 3
 Dr. Nathan Richard George, D.D.S. Dentist - General Practice Medicare: Medicare Enrolled Practice Location: 7726 Lupine Lane, Victor, ID 83455 Phone: 208-787-8100 |
Mr. Tristan Taylor, D.D.S. Dentist Medicare: Not Enrolled in Medicare Practice Location: 7726 Lupine Ln, Victor, ID 83455 Phone: 208-787-8100 Fax: 208-787-8101 |
Elmer Raymond Cherry Iv, D.D.S Dentist Medicare: Medicare Enrolled Practice Location: 7389 S. Hwy. 33 Suite A, Victor, ID 83455 Phone: 208-787-2323 |
News Archive
Potassium citrate effective for prevention and treatment of osteoporosis: Study
The Western diet creates an acidic environment in the body that removes calcium from bones and may contribute to the development of osteoporosis. Healthy adults who consume the standard US diet sustain a chronic, low-grade state of acidosis that worsens with age as kidney function declines, limiting urinary acid excretion. Reto Krapf, MD (University of Basel, in Bruderholz/Basel, Switzerland) and colleagues designed a study to see if daily alkali as potassium citrate supplement tablets might neutralize these effects.
Celldex launches rindopepimut Phase 3 trial in EGFRvIII-positive glioblastoma
Celldex Therapeutics, Inc. today announced that it has launched a pivotal, randomized, double-blind, controlled Phase 3 trial of rindopepimut in patients with surgically resected epidermal growth factor variant III (EGFRvIII)-positive glioblastoma, the "ACT IV Study."
Louise A. Villejo recognized with 2010 Julie and Ben Rogers Award for Excellence in Education
Louise A. Villejo, executive director of the Patient Education Office at The University of Texas MD Anderson Cancer Center, is the recipient of the 2010 Julie and Ben Rogers Award for Excellence in Education.
Onconova advances rigosertib into new Phase II study for refractory MDS
Onconova Therapeutics, Inc., announced today the advancement of the oral formulation of rigosertib, an anti-cancer agent with demonstrated activity in solid tumors and hematologic malignancies, into a new Phase II study. The intravenous (IV) formulation of rigosertib is currently in a pivotal Phase III trial for refractory myelodysplastic syndromes (MDS) in the U.S. and EU.
Clemson University researcher reveals insights into rapid spread of homemade steroids
A Clemson University researcher recently published insights into homemade steroids and steroid trafficking through a study of federal court cases. The research details why homemade steroids became popular and how online tools and cryptocurrency have allowed for their rapid spread.
› Verified 1 days ago